Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
TransCode Therapeutics Inc. (RNAZ) had Normalized Income after Taxes of $-16.76M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-16.79M |
|
-- |
|
-- |
|
$15.66M |
|
$-15.66M |
|
$-1.09M |
|
$-16.75M |
|
$-16.76M |
|
$-16.75M |
|
$-16.75M |
|
$-16.75M |
|
|
Normalized Income after Taxes |
$-16.76M |
$-15.66M |
|
$-15.13M |
|
0.01M |
|
0.01M |
|
$-1320.45 |
|
$-1320.45 |
|
| Balance Sheet Financials | |
$7.09M |
|
$0.05M |
|
$0.20M |
|
$7.29M |
|
$2.77M |
|
-- |
|
$6.54M |
|
$9.31M |
|
$-2.02M |
|
$-2.02M |
|
$-2.02M |
|
0.04M |
|
| Cash Flow Statement Financials | |
$-13.34M |
|
$-0.02M |
|
$16.40M |
|
$2.77M |
|
$5.81M |
|
$3.04M |
|
$1.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
829.97% |
|
829.97% |
|
-229.69% |
|
829.97% |
|
$-54.95 |
|
$-1050.69 |
|
$-1048.97 |
|